Frequency and Predictors of Self-Reported Hypoglycemia in Insulin-Treated Diabetes by Malkani, Samir & Kotwal, Anupam
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2017-08-20 
Frequency and Predictors of Self-Reported Hypoglycemia in 
Insulin-Treated Diabetes 
Samir Malkani 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Endocrine System Diseases Commons, Endocrinology, Diabetes, and Metabolism 
Commons, Immune System Diseases Commons, and the Nutritional and Metabolic Diseases Commons 
Repository Citation 
Malkani S, Kotwal A. (2017). Frequency and Predictors of Self-Reported Hypoglycemia in Insulin-Treated 
Diabetes. Open Access Articles. https://doi.org/10.1155/2017/7425925. Retrieved from 
https://escholarship.umassmed.edu/oapubs/3231 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Research Article
Frequency and Predictors of Self-Reported Hypoglycemia in
Insulin-Treated Diabetes
Samir Malkani1 and Anupam Kotwal2
1Division of Diabetes, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
2Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, 200 First Street SW, Mayo 18, Rochester,
MN 55905, USA
Correspondence should be addressed to Anupam Kotwal; Kotwal.Anupam@mayo.edu
Received 6 June 2017; Accepted 6 July 2017; Published 20 August 2017
Academic Editor: Konstantinos Papatheodorou
Copyright © 2017 Samir Malkani and Anupam Kotwal. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work
is properly cited.
Aims. Hypoglycemia is a limiting factor for achieving stringent glycemic control in diabetes. This study analyzes the frequency and
predictors of hypoglycemia in insulin-treated diabetes in an ambulatory setting. Methods. A retrospective chart review was
performed to study self-monitored blood glucose (SMBG) data for 3 months prior to a patient’s HbA1c test. Results.
Hypoglycemia occurred more frequently in type 1 than in type 2 diabetes; however, 19% of type 2 diabetes patients did
experience at least one episode of severe hypoglycemia. For type 1 diabetes, hypoglycemia had a positive association with
glycemic variability and duration of diabetes and a negative association with HbA1c and lowest blood glucose (BG). For type 2
diabetes, a positive association was noted with glycemic variability and a negative association with age and lowest BG.
Conclusions. Delineating factors predisposing to hypoglycemia in type 2 diabetes is diﬃcult. Lower HbA1c is a potential
predictor of hypoglycemia in type 1 but not in type 2 diabetes. Longer duration of diabetes for type 1 and younger age for type 2
are associated with more hypoglycemia. Glycemic variability portends increased risk for hypoglycemia and should be a focus of
further research.
1. Introduction
Hypoglycemia is a major limiting factor for achieving
stringent glycemic control in diabetes. It inﬂuences self-
management of diabetes with some patients accepting
suboptimal glycemic control to reduce the risk of hypogly-
cemia [1]. Moreover, hypoglycemia is associated with
signiﬁcant morbidity. Severe hypoglycemia can cause sei-
zures and arrhythmias. It is associated with dementia [2],
and it has been linked with poor cardiovascular outcomes
[3] and death [4]. Hypoglycemia has also been shown to
trigger adrenergic discharge and the expression of proin-
ﬂammatory cytokines [5].
Hypoglycemia is common in type1diabetes, and its occur-
rence increases with insulin use in type 2 diabetes [6–10]. It
is a common and potentially dangerous side eﬀect of insulin
therapy; however, its occurrence is not easy to predict. The
majority of our knowledge about severe hypoglycemia
comes from type 1 diabetes. Data on rates and potential risk
factors for severe hypoglycemia in insulin-treated type 2 dia-
betes are relatively scarce and conﬂicting. Clinical trials have
reported low rates of severe hypoglycemia in type 2 diabetes
[11, 12], and population-based studies have reported highly
variable rates [13, 14]. The reported frequency of severe
hypoglycemia in clinical trials may represent only the “tip
of the iceberg” in terms of all episodes. In the case of severe
hypoglycemia, most studies have used its clinical deﬁnition
that was ﬁrst described by the Diabetes Control and Compli-
cations Trial (DCCT), as any hypoglycemia that requires
external assistance [15]. However, reporting of such episodes
by patients, especially those with hypoglycemia unaware-
ness, can be unreliable. Data derived from the frequency of
treated episodes of severe hypoglycemia by emergency
services are similarly inadequate to quantify the overall
incidence, as only 10% of severe episodes are treated in the
hospital. Data from continuous glucose monitoring (CGM)
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studies reveal that even asymptomatic hypoglycemia is
associated with the risk of cardiac arrhythmias [16].
In patients on insulin therapy, inadequate caloric intake,
exercise, renal insuﬃciency, and alcohol ingestion can pre-
cipitate hypoglycemia. In many episodes of hypoglycemia, a
precipitating factor cannot be identiﬁed. Although some phe-
notypic markers are known to predispose patients to hypo-
glycemia, its predictors in insulin-treated diabetes have not
been well studied, especially when these patients are followed
on an ambulatory basis and have not been actively enrolled in
a study. Hypoglycemia unawareness is common in long-
standing diabetes and can lead to serious consequences in
spite of lack of symptoms, and blood glucose testing or
CGM can identify such episodes more reliably. To try and ﬁll
the gaps in knowledge, we conducted this study to analyze
the frequency and potential predictors of self-monitored
hypoglycemia in type 1 and insulin-treated type 2 diabetes
in an ambulatory setting.
2. Material and Methods
2.1. Subjects with Diabetes Mellitus. We performed a cross-
sectional chart review study utilizing the electronic database
of the University of Massachusetts Medical School Diabetes
Clinic. The clinic, which serves residents of central Massa-
chusetts, uses an electronic diabetes management system,
My Care Team™ (MCT) that captures all the patients’ self-
monitored blood glucose (SMBG) data. The system is able
to upload readings from most commercial blood glucose
monitors; data from blood glucose meters is uploaded at each
clinic visit. Diabetic adults who were seen at the clinic
between October 1, 2012, and September 30, 2013, were
eligible if they were on insulin treatment, and their meter
download on MCT showed a SMBG testing frequency of 3
times or more daily. Pregnant women were excluded. The
UMass IRB approved the study proposal. Of the total sample
of 3000 patients, 298 were included in the study based on the
eligibility criteria. Each patient had a hemoglobin A1c
(HbA1c) tested at the visit, and the SMBG data for a 3-
month period prior to the clinic visit was collected. For
patients who had more than one clinic visit during the study
period, the most recent one was used for the purpose of data
collection. Categorical variables assessed were gender, race,
and presence or absence of depression, coronary artery
disease (CAD), hypertension (HTN), nephropathy, and
retinopathy. Nephropathy was deﬁned as albuminuria (spot
urine albumin : creatinine ratio> 300mcg/mg) or progressive
chronic kidney disease, and presence of retinopathy included
all classes of detectable retinopathy. Continuous variables
assessed were age, body mass index (BMI), duration of diabe-
tes, HbA1c, daily insulin dose, number of daily injections,
and SMBG data including minimum SMBG value and
standard deviation (SD) around mean SMBG.
2.2. Identiﬁcation of Hypoglycemic Episodes. Hypoglycemia
was deﬁned as a SMBG reading≤ 70mg/dL [17], and severe
hypoglycemia as a SMBG reading≤ 45mg/dL. All commer-
cial SMBG monitors provide glucose readings such that the
reported result most closely matches that of a laboratory
method measuring serum or plasma glucose [18]. No
distinction was made between asymptomatic and symp-
tomatic hypoglycemic episodes. We calculated the number
hypoglycemic episodes for each patient from their home
glucose meter upload for a 3-month period prior to their
clinic visit. Sequential SMBG readings meeting hypoglyce-
mia criteria recorded within a 2-hour period were consid-
ered as a single episode.
2.3. Statistical Analysis. A database was created with data for
all the variables, and statistical analysis was performed using
the software SPSS. As the independent variables were not dis-
tributed normally, nonparametric tests of signiﬁcance were
utilized. Mann–Whitney U test was used to assess the associ-
ation of categorical independent variables with dependent
variables (frequency of hypoglycemia and severe hypoglyce-
mia). For continuous variables, Spearman’s correlation and
Wilcoxon signed-rank test were used for univariate analysis.
p value ≤ 0.05 was considered signiﬁcant. All probabilities
were two tailed. Multivariate linear regression (as dependent
variables were continuous) was then used for all the associa-
tions that were signiﬁcant on univariate analysis to remove
the eﬀect of confounders. Two separate models were created
using the frequencies of all hypoglycemic episodes and severe
hypoglycemic episodes as dependent variables.
3. Results
3.1. Study Sample. A total of 298 patients with diabetes on
insulin were included for analysis. This included 133 patients
with type 1 and 165 patients with type 2 diabetes. Of the 133
subjects with type 1 diabetes, 47 (35.3%) were using an insu-
lin pump and the rest were on multiple daily injections
(MDI). The characteristics of the subjects including mean
age, gender distribution, and diabetes duration are shown
in Table 1. The group with type 1 diabetes had a signiﬁcantly
lower age, BMI, and duration of diabetes as well as a signiﬁ-
cantly lower percentage of individuals suﬀering from hyper-
tension, CAD, and nephropathy as compared to the group
with type 2 diabetes. This group had a signiﬁcantly higher
mean HbA1c, number of daily insulin injections, daily insu-
lin dose, and SD around mean SMBG (indicator of glycemic
variability) as compared to the group with type 2 diabetes.
There was no statistically signiﬁcant diﬀerence in regard to
gender, daily insulin dose adjusted for BMI, and the percent-
age of individuals with depression or retinopathy between
the two groups. The characteristics of the individuals with
insulin-treated diabetes that were excluded from the study
were similar to those that were included.
3.2. Frequency of Hypoglycemia. All patients with type 1
diabetes and 82% of patients with type 2 diabetes experienced
at least one episode of hypoglycemia. The corresponding
numbers for severe hypoglycemia were 68% for type 1 and
19% for type 2 diabetes. 88% of those with type 1 experienced
more than 10 hypoglycemic episodes compared to 30% with
type 2 diabetes. Those with type 1 diabetes recorded a total of
4583 hypoglycemic episodes that corresponds to a rate of
137.8 (95% CI 135.9 and 139.8) episodes per person per year.
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643 (14%) of these were severe, corresponding to 19.3 (95%
CI 18.6 and 20.1) severe episodes per person per year. In
those with type 2 diabetes, a total of 1517 hypoglycemic
episodes were recorded; of which, 119 (8%) were severe. This
corresponds to an event rate per person per year for hypogly-
cemia and severe hypoglycemia of 36.8 (95% CI 35.9, 37.7)
and 2.9 (95% CI 2.6, 3.2), respectively. Less than 1% of indi-
viduals with type 2 diabetes reported greater than 10 severe
Table 1: Characteristics of patients with insulin-treated diabetes participating in the study.
Patient characteristics
All patients
Mean± SD, range or
n (%) patients
Type 1 diabetes
Mean± SD, range or
n (%) patients
Type 2 diabetes
Mean± SD, range or
n (%) patients
p value
Number of patients (%) 298 (100) 133 (44.6) 165 (55.4) —
Age (years) 60.54± 16.64 52.11± 17.19 67.33± 12.63 0.001
Males 153/145 62 (46.6) 83 (50) 0.606
BMI (kg/m2) [mean± SD] 30.38± 7.45 26.38± 4.66 33.58± 7.73 0.001
Known duration of diabetes
(years) [mean± SD] 21.43± 14.62 25.26± 16.75 18.11± 11.58 0.001
Daily insulin dose (units/day)
[mean± SD] 66.48± 56.05 49.04± 26.91 74.59± 63.80 0.001
Daily insulin dose/BMI
(units/kg/m2/day) [mean± SD] 2.06± 1.35 (n = 210) 1.84± 0.91 (n = 66) 2.16± 1.52 (n = 144) 0.307
HbA1c (%) [mean± SD]
7.77± 1.25
7.94± 1.94 7.64± 1.27
0.032
<7 31 (23.3) 48 (28.9)
7-8 36 (27.1) 59 (35.5)
>8 66 (49.6) 58 (34.9)
SD around mean SMBG 68.71± 17.04 78.93± 2.04 60.47± 1.69 0.001
Lowest SMBG reading
[mean± SD] 49.69± 15.78 40.98± 9.54 56.71± 16.33 0.001
Number of daily insulin
injections [mean± SD]
3.87± 0.93 (median 4,
range 1–6)
4.12± 0.48 (median 4,
range 2–6)
3.73± 1.08 (median 4,
range 1–5)
0.001
MDI 86 (64.7) 165 (100)
—
Insulin pump 47 (35.3) None
HTN 170 (57.0) 47 (35.3) 123 (74.5) 0.001
CAD 74 (24.8) 19 (14.3) 55 (33.3) 0.001
Nephropathy 102 (34.2) 27 (20.3) 75 (45.2) 0.001
Retinopathy (n, %) 63 (21.1) 32 (24.1) 31 (18.8) 0.334
Depression (n, %) 49 (16.4) 16 (12.0) 33 (20.0) 0.091
Caucasians (n, %) 265 (88.9) 128 (96.2) 137 (83.1) 0.001
All hypoglycemic episodes 6100 events
4583 events in 133 (100%)
patients
1517 events in 136 (82%)
patients
0.000
All hypoglycemic episodes per
person per year [OR (95% CI)]
81.9 (80.0 to 82.9) 137.8 (135.9 to 139.8) 36.8 (35.9 to 37.7) 0.000
No hypoglycemic episodes 29 (9.7%) 0 (0%) 29 (17.6%) —
1–10 hypoglycemic episodes in
3 months
269 (90.3%) 16 (12%) 86 (52.1%) —
>10 hypoglycemic episodes in
3 months
167 (56.0%) 117 (88%) 50 (30.3%) —
Severe hypoglycemic episodes 762
643 events in 91 (68%)
patients
119 events in 32 (19%)
patients
0.000
Severe hypoglycemic episodes per
person per year [OR (95% CI)]
10.2 (9.9 to 10.6) 19.3 (18.6 to 20.1) 2.9 (2.6 to 3.2) 0.000
No severe hypoglycemic episodes 175 (58.7%) 42 (31.6%) 133 (80.6%) —
1–10 severe hypoglycemic episodes
in 3 months
123 (41.3%) 73 (54.9%) 31 (18.8%) —
>10 severe hypoglycemic episodes
in 3 months
19 (6.4%) 18 (13.5%) 1 (0.6%) —
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hypoglycemic episodes compared to almost 14% with type 1
diabetes. The frequencies of both all and severe hypoglycemic
episodes were signiﬁcantly higher for type 1 as compared to
type 2 diabetes (p = 0 000 for both).
3.3. Predictors of Hypoglycemia in Type 1 Diabetes. On uni-
variate analysis initially by correlation (for continuous vari-
ables) and then tests of signiﬁcance (Tables 2 and 3), the
frequencies of all and severe hypoglycemia had a signiﬁcant
negative association with the mean HbA1c (p = 0 000 for
both), the lowest BG reading recorded (p = 0 000 for both),
BMI (p = 0 000 for both), and age (p = 0 000 for both). The
frequencies of all and severe hypoglycemia demonstrated a
signiﬁcant positive association with the duration of diabetes
(p = 0 000 for both), daily insulin dose (p = 0 003 and 0.000,
resp.), and glycemic variability (p = 0 000 for both). There
was a positive association with the number of daily insu-
lin injections that was statistically signiﬁcant only for all
hypoglycemia (p = 0 000).
Multivariate linear regression analysis (Table 4) which
adjusted for independently associated variables revealed a
signiﬁcant positive association of the frequencies of all and
severe hypoglycemia with glycemic variability and duration
of diabetes and a signiﬁcant negative association with
HbA1c. When the lowest BG reading was included in this
analysis, it continued to be signiﬁcantly negatively associated
Table 2: Results of nonparametric test (Mann–Whitney U test) for association of categorical independent variables with frequencies of
hypoglycemia and severe hypoglycemia.
Categorical variables Type 1 diabetes Type 2 diabetes
Mann–Whitney U test
Hypoglycemia
[mean± SD] p value
Severe hypoglycemia
[mean± SD] p value
Hypoglycemia
[mean± SD] p value
Severe hypoglycemia
[mean± SD] p value
Females 37.96± 26.40
0.188
5.69± 7.99
0.523
8.16± 9.96
0.617
0.88± 2.66
0.412
Males 30.45± 19.31 3.85± 5.22 10.22± 11.91 0.57± 1.72
Nephropathy absent 36.45± 24.62
0.089
5.10± 7.08
0.162
9.57± 11.84
0.581
0.91± 2.69
0.487
Nephropathy present 26.63± 17.16 3.78± 6.02 8.75± 9.95 0.49± 1.50
Retinopathy absent 35.85± 24.14
0.258
4.94± 7.03
0.524
9.22± 11.68
0.109
0.81± 2.43
0.551
Retinopathy present 30.06± 21.49 4.50± 6.46 9.06± 7.53 0.35± 1.02
On MDI 32.92± 23.43
0.224
4.85± 7.24
0.543
9.30± 11.02
0.085
0.73± 2.25
—
On insulin pump 37.28± 23.84 4.81± 6.23 0.50± 0.71 0.00
HTN absent 35.23± 24.09
0.648
5.08± 6.94
0.377
10.48± 11.60
0.324
0.74± 1.81
0.647
HTN present 33.04± 22.79 4.38± 6.80 8.76± 10.80 0.71± 2.37
CAD absent 35.69± 23.23
0.063
5.12± 7.09
0.132
9.50± 11.08
0.367
0.76± 2.42
0.783
CAD present 27.05± 24.92 3.10± 5.22 8.58± 10.91 0.64± 1.83
Other race 24.60± 11.33
0.435
1.40± 1.34
0.284
10.11± 12.25
0.913
1.28± 2.92
0.326
Caucasians 34.84± 23.87 4.97± 6.97 9.01± 10.76 0.60± 2.06
Depression absent 34.63± 24.07
0.912
4.69± 6.86
0.484
8.56± 10.72
0.047
0.67± 2.29
0.366
Depression present 33.19± 20.21 5.87± 7.13 11.73± 11.89 0.94± 2.03
Diﬀerent categories of
A1c (<7, 7-8, >8) 0.001 0.052 0.507 0.363
Table 3: Results of nonparametric tests Spearman’s correlation (to calculate correlation coeﬃcient) and Wilcoxon signed-rank test (to assess
signiﬁcance with p value) for association of continuous independent variables with frequencies of hypoglycemia and severe hypoglycemia.
Continuous variables
Type 1 diabetes Type 2 diabetes
Hypoglycemia Severe hypoglycemia Hypoglycemia Severe hypoglycemia
Correlation
coeﬃcient ρ
p value
Correlation
coeﬃcient ρ
p value
Correlation
coeﬃcient ρ
p value
Correlation
coeﬃcient ρ
p value
Age (years) −0.2 0.000 −0.2 0.000 −0.03 0.000 −0.01 0.000
BMI −0.1 0.005 −0.1 0.000 −0.1 0.000 −0.2 0.000
Duration of diabetes +0.2 0.000 +0.2 0.000 +0.2 0.000 +0.2 0.000
Daily insulin dose 0.1 (n = 66) 0.003 0.1 (n = 46) 0.000 0.1 (n = 119) 0.000 0.01 (n = 29) 0.000
Daily insulin injections +0.2 0.000 +0.2 0.14 +0.04 0.000 +0.1 0.000
Lowest BG reading −0.7 0.006 −0.9 0.000 −0.8 0.000 −0.7 0.000
SD around mean BG +0.1 0.000 +0.2 0.000 +0.2 0.000 +0.2 0.000
HbA1c −0.4 0.000 −0.2 0.000 −0.1 0.456 −0.04 0.000
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with both all and severe hypoglycemia. The association with
other variables like age, BMI, number of daily insulin injec-
tions, and daily insulin dose did not achieve signiﬁcance in
the regression analysis.
3.4. Predictors of Hypoglycemia in Insulin-Treated Type 2
Diabetes. On univariate analysis, the frequencies of all and
severe hypoglycemia had a signiﬁcant negative association
with the lowest BG reading recorded (p = 0 000 for both),
BMI (p = 0 000 for both), and age (p = 0 000 for both). There
was a negative association with HbA1c that was statistically
signiﬁcant only for severe hypoglycemia (p = 0 000). The fre-
quencies of all and severe hypoglycemia had a signiﬁcant
positive association with the duration of diabetes (p = 0 000
for both), daily insulin dose (p = 0 000 for both), number of
daily insulin injections (p = 0 000 for both), and glycemic
variability (p = 0 000 for both). The frequency of all hypogly-
cemia had a signiﬁcant positive association with the presence
of depression (p = 0 047).
Multivariate linear regression analysis (Table 4), which
adjusted for independently associated variables, revealed a
signiﬁcant negative association of the frequency of all hypo-
glycemia with age. The association with other variables seen
on univariate analysis did not achieve signiﬁcance during
regression analysis. However, when the lowest BG reading
was included in this analysis, it continued to be signiﬁcantly
negatively associated with both all and severe hypoglycemia,
and the positive association of all hypoglycemia with glyce-
mic variability achieved statistical signiﬁcance.
When comparing individuals with type 1 diabetes
using an insulin pump versus those on MDI, there was
no statistically signiﬁcant diﬀerence between the frequen-
cies of all or severe hypoglycemia and mean HbA1C value.
In regard to diﬀerent therapeutic regimens, there was no
statistically signiﬁcant diﬀerence in hypoglycemia frequency
when comparing diﬀerent MDI regimens for either type 1
or type 2 diabetes.
4. Discussion
Although hypoglycemia is a common complication of insulin
treatment in diabetes, very few studies have evaluated the
frequency and predictors of self-reported hypoglycemia on
an ambulatory basis, especially in insulin-treated type 2 dia-
betes. The present study examined self-reported hypoglyce-
mia in a sample of patients with insulin-treated diabetes
who were being managed at a university hospital diabetes
clinic and accurately represented the population base. Our
results are based on hypoglycemia recorded by the subject
whether or not they experienced symptoms. SMBG fre-
quency of at least 3 times a day reduced the likelihood of
missing any episodes of hypoglycemia. The over recording
of hypoglycemia in the initial data was corrected by counting
SMBG readings≤ 70mg/dL recorded within a 2-hour period
as one hypoglycemic episode unless there was a read-
ing> 70mg/dL in between them. It is not surprising that
our patients with type 1 diabetes reported more hypoglyce-
mic episodes as compared to those with type 2 diabetes.
However, compared with previous studies of both type 1
[19, 20] and type 2 diabetes [11, 14, 21], the event rates and
the proportion of subjects experiencing hypoglycemic events
in our study were higher, especially in type 2 diabetes with
19% experiencing an episode of severe hypoglycemia. The
possible reasons for this could be the longer duration of dia-
betes in our patients, being followed on an ambulatory basis
as compared to being enrolled in a clinical trial, and the fact
that many other studies have deﬁned severe hypoglycemia on
symptoms and not BG values. The rates of severe hypoglyce-
mia in insulin-treated type 2 diabetes are reported to be low
[11, 14, 21], but these have been recorded in the context of
clinical trials and often in people with a short duration of
insulin therapy.
Insulin use has been linked to higher likelihood of
experiencing hypoglycemia; however, within the group of
insulin-treated diabetes, the predictors of hypoglycemia
remain unclear. In type 1 diabetes, a negative association of
hypoglycemia with HbA1c has been reported by several stud-
ies [15, 22, 23]. In type 2 diabetes, either no association or a
positive association of hypoglycemia with HbA1c has been
reported [8, 20, 24] except in the PREDICTIVE trial which
demonstrated a negative association between the two in both
type 1 and type 2 diabetes [23]. Within the intensive treat-
ment arm of the ACCORD trial for type 2 diabetes, a higher
HbA1c and lower change in HbA1c from baseline were
Table 4: Multivariate regression analysis using hypoglycemic episodes and severe hypoglycemic episodes as dependent variables and
variables that achieved signiﬁcance on univariate analysis as independent variables.
Variables signiﬁcant on
univariate analysis
Type 1 diabetes Type 2 diabetes
Hypoglycemia
(beta; p value)
Severe hypoglycemia
(beta; p value)
Hypoglycemia
(beta; p value)
Severe hypoglycemia
(beta; p value)
Age −0.25; 0.28 −0.09; 0.23 −0.26; 0.032 −0.01; 0.84
BMI 1.27; 0.14 0.11; 0.71 −0.27; 0.10 −0.03; 0.41
Duration of diabetes 0.46; 0.042 0.16; 0.037 0.18; 0.11 −0.01; 0.65
Total insulin dose 0.24; 0.11 0.02; 0.72 0.01; 0.74 0.002; 0.79
Number of daily
injections
1.95; 0.76 — −0.89; 0.44 0.05; 0.84
SD around mean BG 0.43; 0.022 0.15; 0.023 0.07; 0.22 0.01; 0.50
HbA1c −9.69; 0.010 −3.19; 0.015 — −0.09; 0.71
Depression — — −1.63; 0.61 —
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associated with a higher rate of occurrence of hypoglycemia
[25]. In our study, after adjusting for independent variables,
lower HbA1c was a potential predictor of hypoglycemia in
type 1 but not in type 2 diabetes. Glycemic variability has
been assessed by studies using diﬀerent parameters, SD
around mean BG being the best demonstrated for SMBG
data. In our study, this was a signiﬁcant predictor for hypo-
glycemia. A history of previous severe hypoglycemia has
been reported to be a risk factor for severe hypoglycemia
[15, 26]. Similarly, our study found a signiﬁcant association
between experiencing a low PG reading and increased fre-
quency of all and severe hypoglycemic episodes in both type
1 and type 2 diabetes. Also, the distribution of hypoglycemia
in our study was highly skewed with a small proportion of
patients accounting for the majority of episodes.
In the UKPDS trial, hypoglycemia was more frequent in
younger patients, females, non-obese patients and those with
positive islet cell antibodies [11]. Our study also showed a
higher frequency of hypoglycemia in younger type 2 diabetes
patients, but there was no signiﬁcant association with gender
or BMI in regression analysis. However these two studies are
not exactly comparable as we studied only insulin-treated
diabetics with longer diabetes duration. Other studies have
reported hypoglycemia in type 2 diabetes to be linked to lon-
ger duration of diabetes [7, 20] which we found on univariate
but not multivariate analysis. The increased occurrence of
hypoglycemia in patients with longer duration of diabetes
could be related to the accompanying hypoglycemia-
associated autonomic failure (HAAF). Depression has been
associated with severe hypoglycemia in type 2 diabetes [27];
in our study, this association was observed on univariate
analysis but did not hold up in multivariate regression
analysis. In type 2 diabetes, a lower BMI is associated with
hypoglycemia in some studies [23], and in our cohort, this
relationship was observed only in univariate, but not in mul-
tivariate analysis. Our observation of higher rates of hypogly-
cemia in younger type 2 diabetes patients can be explained by
the higher insulin sensitivity in this group. There was no
signiﬁcant diﬀerence in the frequency of hypoglycemia or
mean HbA1c between those with type 1 diabetes that were
on an insulin pump versus those on MDI; however the study
was not powered to assess this. Similar ﬁndings have been
reported by a recent meta-analysis [28].
5. Conclusions
Insulin treatment of diabetes increases the likelihood of
experiencing hypoglycemia. We studied a cohort of patients
with relatively well-controlled diabetes in terms of their
HbA1c values, who had diabetes for a long duration thus
increasing their risk of HAAF. Even though hypoglycemia
is more common in type 1 diabetes, it continues to remain
an important complication of insulin treatment in type 2 dia-
betes. In type 1 diabetes, striving for a lower HbA1c increases
the risk of hypoglycemia. In addition, increased glycemic
variability and longer duration of diabetes are signiﬁcant
potential predictors of hypoglycemia. In type 2 diabetes, fac-
tors predisposing to hypoglycemia are interdependent and
we found it diﬃcult to delineate them separately. However,
we did ﬁnd higher glycemic variability to be associated with
a higher frequency of hypoglycemic episodes in this group.
There seems to be a positive association of hypoglycemia
with depression in type 2 diabetes, which needs to be further
explored. In our study, younger insulin-treated type 2 dia-
betics experienced more hypoglycemic episodes, which is
contrary to some other studies. Experiencing a hypoglycemic
episode increases the risk of more hypoglycemia in both type
1 and type 2 diabetes. Very frequent hypoglycemia occurs in
a small proportion of patients, and these are the ones that
require the greatest attention to avoid hypoglycemia. Glyce-
mic variability, which is an indicator of poor glycemic control
rather than tight glycemic control, portends increased risk
for hypoglycemia. Studies that focus on glycemic variability
and interventions to prevent hypoglycemia in high-risk
patients are needed.
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